{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:29:37Z","timestamp":1759483777912},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2015,5,12]],"date-time":"2015-05-12T00:00:00Z","timestamp":1431388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0122587","type":"journal-article","created":{"date-parts":[[2015,5,12]],"date-time":"2015-05-12T18:00:06Z","timestamp":1431453606000},"page":"e0122587","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts &lt; 200 Cells\/\u03bcL: TB-HAART Study, a Randomized Clinical Trial"],"prefix":"10.1371","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct01315301","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Wondwossen","family":"Amogne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Getachew","family":"Aderaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abiy","family":"Habtewold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Getnet","family":"Yimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eyasu","family":"Makonnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alemayhu","family":"Worku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Sonnerborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Aklillu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Lindquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,5,12]]},"reference":[{"key":"ref1","article-title":"Global Tuberculosis Control","year":"2011"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0140-6736(93)91346-N","article-title":"Spectrum of immunodeficiency in HIV-1-infected patients with pulmonary tuberculosis in Zaire","volume":"342","author":"Y Mukadi","year":"1993","journal-title":"Lancet"},{"key":"ref3","first-page":"231","article-title":"Tuberculosis should not be considered an AIDS-defining illness in areas with a high tuberculosis prevalence","volume":"6","author":"M Badri","year":"2002","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/01.qai.0000225729.79610.b7","article-title":"CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment","volume":"42","author":"CB Holmes","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/QAD.0b013e328013f632","article-title":"Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda","volume":"21","author":"D Moore","year":"2007","journal-title":"AIDS"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1097\/QAD.0b013e32801086b0","article-title":"Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi","volume":"20","author":"R Zachariah","year":"2006","journal-title":"AIDS"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/QAD.0b013e328325d115","article-title":"Effect of pulmonary tuberculosis on mortality in patients receiving HAART","volume":"23","author":"D Westreich","year":"2009","journal-title":"AIDS"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0140-6736(06)68383-9","article-title":"Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment","volume":"367","author":"EL Corbett","year":"2006","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00002030-200101260-00002","article-title":"Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa","volume":"15","author":"YD Mukadi","year":"2001","journal-title":"AIDS"},{"key":"ref10","unstructured":"Tamura M, Khun KE, Yuos BH. High prevalence\/incidence of TB and poor outcomes of TB treatment among people living with HIV\/AIDS (PLWHA) in Phnom Penh, Cambodia.Presentedat the XV International AIDS Conference, Bangkok, Thailand, July 11\u201316, 2004. Abstract (<ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.Iasociety.org\/Default.aspx?PageId=11&abstractId=2173528\" xlink:type=\"simple\">http:\/\/www.Iasociety.org\/Default.aspx?PageId=11&amp;abstractId=2173528<\/ext-link>)."},{"key":"ref11","unstructured":"Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/wwwaidsinfonihgov\/ContentFiles\/AdultandAdolescentGL.pdf\" xlink:type=\"simple\">http:\/\/wwwaidsinfonihgov\/ContentFiles\/AdultandAdolescentGL.pdf<\/ext-link> (Accessed12Feb2012)."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","article-title":"Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis","volume":"365","author":"FX Blanc","year":"2011","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1468-1293.2008.00636.x","article-title":"British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008","volume":"9","author":"BG Gazzard","year":"2008","journal-title":"HIV Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0905848","article-title":"Timing of initiation of antiretroviral drugs during tuberculosis therapy","volume":"362","author":"Karim SS Abdool","year":"2010","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1056\/NEJMoa1014181","article-title":"Integration of antiretroviral therapy with tuberculosis treatment","volume":"365","author":"Karim SS Abdool","year":"2011","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","article-title":"Timing of antiretroviral therapy for HIV-1 infection and tuberculosis","volume":"365","author":"DV Havlir","year":"2011","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/QAI.0b013e31825b5e06","article-title":"Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study","volume":"60","author":"W Manosuthi","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref18","unstructured":"WHO.Treatment of Tuberculosis:guidelines-4th ed. Geneva, 2009. WHO\/HTM\/TB\/2009.420."},{"key":"ref19","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1473-3099(08)70184-1","article-title":"Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings","volume":"8","author":"G Meintjes","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"JJ Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"ref21","unstructured":"WHO. Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care (ISTC). The Hague:Tuberculosis Coalition for Technical Assistance, 2006."},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1086\/424676","article-title":"Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy","volume":"190","author":"K Dheda","year":"2004","journal-title":"J Infect Dis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e20755","DOI":"10.1371\/journal.pone.0020755","article-title":"Assessing tuberculosis case fatality ratio: a meta-analysis","volume":"6","author":"M Straetemans","year":"2011","journal-title":"PLoS One"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/00365540701474508","article-title":"Pneumocystis jiroveci pneumonia and other pulmonary infections in TB smear-negative HIV-positive patients with atypical chest X-ray in Ethiopia","volume":"39","author":"G Aderaye","year":"2007","journal-title":"Scand J Infect Dis"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/hiv.12073","article-title":"Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV\/tuberculosis-coinfected patients: results from the TREAT Asia HIV Observational Database","volume":"15","author":"SH Han","year":"2014","journal-title":"HIV Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"D Yee","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/cid\/cir230","article-title":"Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)\u2014associated tuberculous meningitis","volume":"52","author":"ME Torok","year":"2011","journal-title":"Clin Infect Dis"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/thx.2006.058867","article-title":"Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection","volume":"61","author":"RA Breen","year":"2006","journal-title":"Thorax"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1164\/ajrccm.157.6.9711039","article-title":"Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus","volume":"157","author":"JR Ungo","journal-title":"Am J Respir Crit Care Med1998"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/hep.510310129","article-title":"Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection","volume":"31","author":"WM Wong","year":"2000","journal-title":"Hepatology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/0016-5085(90)90846-S","article-title":"Isoniazid-rifampin-induced hepatitis in hepatitis B carriers","volume":"98","author":"JC Wu","year":"1990","journal-title":"Gastroenterology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1097\/01.aids.0000432456.14099.c7","article-title":"Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial","volume":"27","author":"D Laureillard","year":"2013","journal-title":"AIDS"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1086\/596764","article-title":"Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance","volume":"48","author":"G Meintjes","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1097\/QAD.0b013e3282f1be39","article-title":"Hepatic involvement with tuberculosis-associated immune reconstitution disease","volume":"21","author":"SD Lawn","year":"2007","journal-title":"AIDS"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/01.aids.0000434936.57880.cd","article-title":"The effect of tuberculosis treatment on virologic and CD4+ cell count response to combination antiretroviral therapy: a systematic review","volume":"28","author":"HM Soeters","year":"2014","journal-title":"AIDS"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1164\/ajrccm\/136.3.570","article-title":"Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival","volume":"136","author":"RE Chaisson","year":"1987","journal-title":"Am Rev Respir Dis"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(95)90519-7","article-title":"Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d&apos;Ivoire","volume":"345","author":"AN Ackah","year":"1995","journal-title":"Lancet"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0035-9203(95)90668-1","article-title":"The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia","volume":"89","author":"AM Elliott","year":"1995","journal-title":"Trans R Soc Trop Med Hyg"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0122587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T06:58:01Z","timestamp":1540277881000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0122587"}},"subtitle":[],"editor":[{"given":"D William","family":"Cameron","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,5,12]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,5,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0122587","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,12]]}}}